Holen Sie sich die Stockscreener-App
66.92
2.26%
1.48
Handel nachbörslich:
66.92
Schlusskurs vom Vortag:
$65.44
Offen:
$64.81
24-Stunden-Volumen:
962.53K
Relative Volume:
1.43
Marktkapitalisierung:
$4.29B
Einnahmen:
$136.86M
Nettoeinkommen (Verlust:
$-168.69M
KGV:
-23.81
EPS:
-2.81
Netto-Cashflow:
$-113.49M
1W Leistung:
+7.43%
1M Leistung:
+5.12%
6M Leistung:
+11.40%
1J Leistung:
+58.05%
1-Tages-Spanne:
$64.81
$67.75
1-Wochen-Bereich:
$60.80
$67.75
52-Wochen-Spanne:
$40.46
$69.89
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Firmenname
Rhythm Pharmaceuticals Inc
Sektor
Branche
Telefon
857-264-4280
Adresse
222 BERKELEY STREET, BOSTON, MA
Vergleichen Sie RYTM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
66.92 | 4.29B | 136.86M | -168.69M | -113.49M | -2.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-03-05 | Fortgesetzt | Stifel | Buy |
| 2025-01-02 | Eingeleitet | Jefferies | Buy |
| 2024-12-20 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-21 | Eingeleitet | Guggenheim | Buy |
| 2024-09-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-17 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-05-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-08-08 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-05 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-06-17 | Bestätigt | Needham | Buy |
| 2022-03-02 | Fortgesetzt | Stifel | Buy |
| 2022-02-17 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | Fortgesetzt | Goldman | Neutral |
| 2021-08-04 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-08-04 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-01-08 | Eingeleitet | Goldman | Sell |
| 2019-07-12 | Hochstufung | Stifel | Hold → Buy |
| 2019-07-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-03-13 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-09-07 | Fortgesetzt | Morgan Stanley | Overweight |
| 2018-06-25 | Bestätigt | Needham | Buy |
| 2018-06-15 | Bestätigt | Needham | Buy |
| 2017-10-30 | Eingeleitet | BofA/Merrill | Buy |
| 2017-10-30 | Eingeleitet | Needham | Buy |
Alle ansehen
Rhythm Pharmaceuticals Inc Aktie (RYTM) Neueste Nachrichten
GAMMA Investing LLC Grows Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
SG Americas Securities LLC Buys Shares of 19,667 Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
22,192 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Bought by Assenagon Asset Management S.A. - Defense World
(RYTM) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives $76.62 Average Target Price from Brokerages - Defense World
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Acquired by Rhumbline Advisers - Defense World
Rhythm Pharma stock soars to all-time high of $69.7 By Investing.com - Investing.com South Africa
Rhythm Pharmaceuticals at Goldman Sachs Conference: Strategic Focus on Rare Diseases - Investing.com Nigeria
Rhythm Pharma stock soars to all-time high of $69.7 - Investing.com Australia
Transcript : Rhythm Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - MarketScreener
Rhythm Pharmaceuticals (RYTM) Gets Price Target Upgrade by Stifel Amid Obesity Drug Optimism - MSN
Millennium Management LLC Sells 21,718 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target - Yahoo Finance
Jefferies maintains buy rating on Rhythm Pharmaceuticals stock By Investing.com - Investing.com UK
Citizens JMP maintains $84 target on Rhythm Pharmaceuticals stock By Investing.com - Investing.com UK
Rhythm Pharmaceuticals at Jefferies Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals at Jefferies Conference: Strategic Pipeline Insights - Investing.com
(RYTM) Proactive Strategies - news.stocktradersdaily.com
Stifel Nicolaus Issues Positive Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price - Defense World
Rhythm Pharmaceuticals (RYTM) Target Price Raised by Stifel Anal - GuruFocus
12 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know - Benzinga
Rhythm Pharmaceuticals (RYTM) Stock Jumps Nearly 6%: What's Driving the Upbeat Tempo? - Daily Chhattisgarh News
Stifel raises Rhythm Pharma stock target to $94, keeps Buy rating - Investing.com Canada
Rhythm Pharmaceuticals (RYTM) Target Price Boosted by Analyst | - GuruFocus
Rhythm Pharmaceuticals (RYTM) Target Price Boosted by Analyst | RYTM Stock News - GuruFocus
Ameriprise Financial Inc. Purchases 11,480 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
POMC Deficiency Obesity Market on Track for Major Expansion - openPR.com
(RYTM) Investment Analysis - news.stocktradersdaily.com
Deutsche Bank AG Has $2.73 Million Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Gotham Asset Management LLC Sells 2,685 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives $75.38 Consensus Price Target from Analysts - Defense World
Rhythm Pharmaceuticals Announces New Data Presentations on Patie - GuruFocus
(RYTM) On The My Stocks Page - news.stocktradersdaily.com
RYTM Shows Positive Results in Hypothalamic Obesity Treatment | - GuruFocus
RYTM Shows Positive Results in Hypothalamic Obesity Treatment | RYTM Stock News - GuruFocus
Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program - GlobeNewswire
New Clinical Data: Rhythm's Obesity Drug Achieves 23% Weight Loss in Real-World Study, FDA Filing Coming Q3 - Stock Titan
Raymond James Financial Inc. Buys New Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Rhythm pharmaceuticals outlines Q3 2025 filing for acquired hypothalamic obesity treatment - MSN
HC Wainwright Has Negative Estimate for RYTM Q2 Earnings - Defense World
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2025 Earnings Call Transcript - Insider Monkey
Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Down 6.6% on Disappointing Earnings - Defense World
Needham & Company LLC Increases Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $72.00 - Defense World
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates - MSN
Rhythm Pharmaceuticals Inc (RYTM) Q1 2025 Earnings Call Highlights: Strong IMCIVREE Sales and ... - Yahoo Finance
Rhythm Pharmaceuticals Q1 2025 slides: Revenue grows 45% as HO program advances - Investing.com Canada
RHYTHM PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Rhythm Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings) - Benzinga
Rhythm Pharmaceuticals (RYTM) Price Target Raised by Needham | RYTM Stock News - GuruFocus
Rhythm Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Rhythm Pharmaceuticals misses Q1 2025 EPS estimates - Investing.com
Finanzdaten der Rhythm Pharmaceuticals Inc-Aktie (RYTM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Rhythm Pharmaceuticals Inc-Aktie (RYTM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| German Christopher Paul | Corporate Controller & CAO |
Jun 10 '25 |
Sale |
67.19 |
2,069 |
139,016 |
1,889 |
| Cramer Pamela J. | Chief Human Resources Officer |
Jun 06 '25 |
Option Exercise |
6.80 |
7,031 |
47,811 |
26,240 |
| Cramer Pamela J. | Chief Human Resources Officer |
Jun 06 '25 |
Sale |
68.05 |
7,031 |
478,435 |
19,209 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):